A later amendment corrects this filing, so the terms on this page may be out of date. See the latest version (2026-03-11) →
What happened
HLB bioStep reported consolidated results for FY2025: revenue of US$51.1M (+27.3% year on year), an operating loss of US$5.86M and a net loss of US$8.34M.
Korean rules require this filing when revenue or profit moves 30% or more from the prior year (15% for large companies). The figures are the company's own and may not be audited yet.
| Revenue | US$51.1M |
|---|---|
| Revenue vs a year earlier | +27.3% |
| Operating profit | −US$5.86M |
| Net income | −US$8.34M |
| Period | FY2025 (consolidated) |
| Filed | 2026-02-02, Change of 30% or more in revenue or profit/loss structure (15% for large companies) |
| Source | DART rcept 20260202901367 → open original filing |
Versions of this filing
- 2026-02-02Original (this page)
- 2026-03-11Amendment 1
Source: DART. Information only, not investment advice.